A recent report with a relatively larger cohort of ccRCC patients (n = 94) also consistently showed an increased serum hepcidin level in ccRCC patients compared to non-genitourinary or non-anemic patients (Traeger et al., 2019). The gene discussed is HAMP; the disease is nonpapillary renal cell carcinoma.